The Latest Hepatology Medical Journal Articles

Keep up to date with the latest in hepatology as a sub-specialty of gastroenterology. Check out the latest hepatology articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily.

• Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.17th November 2020
  Systemic inflammation promotes the development of clinical events in patients with advanced chronic liver disease (ACLD). We assessed whether (1) non-selective beta blocker (NSBB) treatment initiation impacts biomarkers of systemic inflammation and (2) whether these changes in systemic inflammation predict complications and mortality.Biomarkers of systemic inflammation, that is, white blood cell count (WBC), C reactive […]
• Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.16th November 2020
  To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with advanced hepatocellular carcinoma (HCC).ASCO convened an Expert Panel to conduct a systematic review of published phase III randomized controlled trials (2007-2020) on systemic therapy for advanced HCC and provide recommended care options for this patient population.Nine phase III randomized […]
• IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.16th November 2020
  IL-17A-producing T cells are present in autoimmune cholestatic liver diseases; however, little is known about the contribution of IL-17 to periductal immune responses. Here we investigated the role of IL-17 produced by antigen specific CD8+ T cells in a mouse model of cholangitis and in vitro in human cholangiocyte organoids.K14-OVAp mice express a MHC I […]
• ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma.16th November 2020
  The tumour microenvironment shapes tumour growth through cellular communications that include both direct interactions and secreted factors. The aim of this study was to characterize the impact of the secreted glycoprotein ADAMTSL5, whose role in cancer has not been previously investigated, on hepatocellular carcinoma (HCC).ADAMTSL5 methylation status was evaluated through bisulfite sequencing, and publicly available […]
• The balance of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis.16th November 2020
  Cancer-associated fibroblasts (CAF), key constituents of the tumor microenvironment, either promote or restrain tumor growth. Attempts to therapeutically target CAFs have been hampered by our incomplete understanding of these functionally heterogeneous cells. Key growth factors in the intestinal epithelial niche, bone morphogenetic proteins (BMPs), also play a critical role in colorectal cancer (CRC) progression. However, […]
• Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.16th November 2020
  In 2016, of the estimated 257 million people living with chronic hepatitis B virus (HBV) infection worldwide, only a small proportion was diagnosed and treated. The insufficiency of information on the proportion of people infected with HBV who are eligible for treatment limits the interpretation of global treatment coverage. We aimed to estimate the proportion […]
• Effectiveness of capsule endoscopy and double-balloon enteroscopy in suspected complicated celiac disease.15th November 2020
  Complicated celiac disease (CCD) is a rare but severe condition with a poor prognosis. Guidelines recommend use of capsule endoscopy (CE) to explore the small bowel (SB), followed by a double-balloon enteroscopy (DBE) in selected cases with suspected CCD. Our study aims to evaluate the diagnostic yield of CE and DBE in identifying and monitoring […]
• Impact of gastric electrical stimulation on economic burden of refractory vomiting: a French nationwide multicentre study.15th November 2020
  Medico-economic data of patients suffering from chronic nausea and vomiting are lacking. In these patients, gastric electrical stimulation (GES) is an effective, but costly treatment.The aim of this study was to assess the efficacy, safety and medico-economic impact of Enterra™ therapy in patients with chronic medically refractory nausea and vomiting.Data were collected prospectively from patients […]
• The overlap between irritable bowel syndrome and organic gastrointestinal diseases.15th November 2020
  Irritable bowel syndrome (IBS) is a common functional bowel disorder characterised by symptoms of recurrent abdominal pain associated with a change in bowel habit. This condition is one of the most frequent reasons to seek a gastroenterology consultation in primary and secondary care. The diagnosis of IBS is made by identifying characteristic symptoms, as defined […]
• Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B.14th November 2020
  In chronic HBV infection, exhausted HBV-specific CD8 T cells express misregulated mitochondrion and proteasome functions. To better characterize the potential involvement of deregulated protein degradation mechanisms in T cell exhaustion we analyzed lysosome-mediated autophagy in HBV-specific CD8 T cells. Bioactive compounds able to target simultaneously both mitochondrial and proteostasis functions were tested to identify optimal […]
• Outcomes following transplantation of HCV-seropositive livers to HCV-seronegative recipients.14th November 2020
  Grafts from hepatitis C virus (HCV)-seropositive donors can now be considered for liver transplant (LT) due to the advent of direct-acting antiviral agents (DAA). We report our multicenter experience evaluating the use of HCV-seropositive donors to HCV-seronegative recipients LT.This is a prospective multicenter observational study to evaluate adult HCV-seronegative LT recipients who received grafts from […]
• A novel waitlist dropout score for hepatocellular carcinoma – identifying a threshold that predicts worse post-transplant survival.14th November 2020
  It has been suggested that patients with hepatocellular carcinoma (HCC) at high risk of waitlist dropout would have done poorly after liver transplantation (LT) due to tumor aggressiveness. To test this hypothesis, we analyzed risk of waitlist dropout among HCC patients in long wait regions (LWR) to create a dropout risk score, and applied this […]
• Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity.14th November 2020
  HBeAg seroconversion during the natural history of chronic hepatitis B (CHB) is associated with a strong drop in serum HBV DNA levels and a reduction of intrahepatic covalently closed circular DNA (cccDNA) content. Of particular interest is the transition to HBeAg-negative chronic infection (ENCI). ENCI, previously known as inactive carrier state, is characterized by very […]
• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.13th November 2020
  Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited. The efficacy and safety of the glucagon-like peptide-1 receptor agonist semaglutide in patients with NASH is not known.We conducted a 72-week, double-blind phase 2 trial involving patients with biopsy-confirmed NASH and liver fibrosis of stage […]
• Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.13th November 2020
  Spinal muscular atrophy (SMA) is an autosomal recessive, childhood-onset motor neuron disease, fatal in its most severe forms. In addition to neuromuscular degeneration, organ involvement, including the liver, may also be present. Onasemnogene abeparvovec (OA) is a gene therapy that addresses SMA’s root cause. In pivotal mouse toxicology studies, the liver was identified a major […]
• The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.12th November 2020
  The Latin American Association for the Study of the Liver (Asociación Latinoamericana para el Estudio del Hígado; ALEH) represents liver professionals in Latin America with the mission of promoting liver health and quality patient care by advancing the science and practice of hepatology and contributing to the development of a regional health policy framework. Fatty […]
• Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa.12th November 2020
  With the increasing prevalence of obesity and type 2 diabetes, fatty liver disease associated with metabolic dysfunction is a global health problem, especially because it is one of the earliest consequences of obesity and it precedes diabetes development. Fatty liver disease associated with metabolic dysfunction is of particular concern in the Middle East and north […]
• ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis.12th November 2020
  Mitochondrial dysfunction plays a dominant role in the pathogenesis of alcoholic liver disease (ALD); however, the underlying mechanisms remain to be fully understood. We previously found that hepatic activating transcription factor 4 (ATF4) activation was associated with mitochondrial dysfunction in ALD. This study aimed to investigate the function and mechanism of ATF4 in alcohol-induced hepatic […]
• Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.12th November 2020
  Inflammatory bowel disease (IBD) is increasing in prevalence in resource-limited settings in Asia. Although the prevalence of IBD is lower in these settings than in high-income countries, the high disease burden due to large population size is projected to overtake that of high-income countries in the near future. Unique challenges exist for diagnosing and managing […]
• Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.12th November 2020
  Over the 21st century, inflammatory bowel disease (IBD) has become a global disease with increasing prevalence reported in the Asian subcontinent as a result of rapid urbanisation, industrialisation, and westernisation of lifestyles. Although rates of surgery have shown a temporal decrease globally because of the increasing availability of new drugs and early initiation of effective […]
• Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16.11th November 2020
  Exosomes released from tumour cells are packed with unique RNA and protein cargo, and they are emerging as an important mediator in the communication network that promotes tumour progression. The facultative intracellular bacterium Fusobacterium nucleatum (Fn) is an important colorectal cancer (CRC)-associated bacterium. To date, the function of exosomes from Fn-infected CRC cells has not […]
• Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function.10th November 2020
  The intestinal microbiome affects the prevalence and pathophysiology of a variety of diseases ranging from inflammation to cancer. A reduced taxonomic or functional diversity of the microbiome was often observed in association with poorer health outcomes or disease in general. Conversely, factors or manifest diseases that determine the long-term stability or instability of the microbiome […]
• Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.9th November 2020
  All randomised phase 3 studies of selective internal radiation therapy for advanced hepatocellular carcinoma published to date have reported negative results. However, these studies did not use personalised dosimetry. We aimed to compare the efficacy of a personalised versus standard dosimetry approach of selective internal radiation therapy with yttrium-90-loaded glass microspheres in patients with hepatocellular […]
• Hepatokines and adipokines in NASH-related hepatocellular carcinoma.8th November 2020
  The incidence of hepatocellular carcinoma (HCC) is increasing in industrialized societies; this is likely secondary to the increasing burden of non-alcoholic fatty liver disease (NAFLD) and the metabolic syndrome. Cumulative studies suggest that NAFLD-related HCC may also develop in non-cirrhotic livers. However, the prognosis and survival of NAFLD-associated HCC does not differ from HCC with […]
• The Next EPISOD: Trends in Utilization of Endoscopic Sphincterotomy for Sphincter of Oddi Dysfunction from 2010-2019.8th November 2020
  For years, the endoscopic management of the disorder formerly known as Type III Sphincter of Oddi Dysfunction (SOD) had been controversial. In 2013, the results of the Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) trial demonstrated that there was no benefit associated with endoscopic sphincterotomy for patients with Type III SOD. We […]
• ALTERATIONS IN THE DUODENAL FLUID MICROBIOME OF PATIENTS WITH PANCREATIC CANCER.8th November 2020
  The tumor microbiome of patients with pancreas ductal adenocarcinoma (PDAC) includes bacteria normally present in the upper gastrointestinal tract. If the predominant source of intratumoral bacteria in patients with PDAC is retrograde migration from the duodenum, duodenal fluid could be a representative biospecimen for determining microbiome profiles of patients with PDAC or at risk of […]
• Quality of colonoscopy is associated with adenoma detection and post-colonoscopy colorectal cancer prevention in Lynch syndrome.6th November 2020
  Colonoscopy reduces colorectal (CRC) incidence and mortality in Lynch syndrome (LS) carriers. However, a high incidence of post-colonoscopy CRC (PCCRC) has been reported. Colonoscopy is highly dependent on operator skill and subject to quality variability. We aimed to evaluate the impact of key colonoscopy quality indicators on adenoma detection and prevention of PCCRC in LS.We […]
• Safety and efficacy of cold snare polypectomy without submucosal injection for large sessile serrated lesions: a prospective study.5th November 2020
  Cold snare polypectomy (CSP) has become the standard resection method for small colorectal polyps (<10 mm). Sessile serrated lesions (SSL) have low prevalence of advanced histology irrespective of size, and thus could be amenable to CSP. In this study, we evaluated the safety and efficacy of CSP for SSLs ≥10 mm.Between November 2018 and January […]
• Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma.5th November 2020
  18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the standard technique to define minimal residual disease (MRD) status outside the bone marrow (BM) in patients with multiple myeloma (MM). This study aimed to define criteria for PET complete metabolic response after therapy, jointly analyzing a subgroup of newly diagnosed transplantation-eligible patients with MM […]
• CRIg+ macrophages prevent gut microbial DNA-containing extracellular vesicle-induced tissue inflammation and insulin resistance.5th November 2020
  Liver CRIg+ (complement receptor of the immunoglobulin superfamily) macrophages play a critical role in filtering bacteria and their products from circulation. Translocation of microbiota-derived products from an impaired gut barrier contributes to the development of obesity-associated tissue inflammation and insulin resistance. However, the critical role of CRIg+ macrophages in clearing microbiota-derived products from bloodstream in […]
• HIGH-RESOLUTION MANOMETRY THRESHOLDS AND MOTOR PATTERNS AMONG ASYMPTOMATIC INDIVIDUALS.4th November 2020
  High-resolution manometry (HRM) is the current standard for characterization of esophageal body and esophagogastric junction (EGJ) function. We aimed to examine the prevalence of abnormal esophageal motor patterns in health, and to determine optimal thresholds for software metrics across HRM systems.Manometry studies from asymptomatic adults were solicited from motility centers worldwide, and were manually analyzed […]
• Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.4th November 2020
  Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is now approved by Food and Drug Administration (FDA) for HCC patients. We evaluated the therapeutic efficacy of cabozantinib, either alone or in combination, in vitro and in vivo.Human HCC cell lines and […]
• Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study.3rd November 2020
  Survivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide.The PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe. Risks […]
• Tumor-derived adenosine promotes macrophage proliferation in human hepatocellular carcinoma.2nd November 2020
  Macrophages (Mφ) represent the major components of tumor tissues and play an important role in both tumor progression and therapeutic response. Although tumor Mφ are generally considered to be derived from circulating monocytes, emerging evidence indicates that tissue Mφ pools can be maintained by self-renewal. We aimed to elucidate the contribution, phenotype, and regulatory mechanisms […]
• Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease.2nd November 2020
  Recently, a group of hepatologists proposed to rename non-alcoholic fatty liver disease (NAFLD) as metabolic associated fatty liver disease (MAFLD) with modified diagnostic criteria. We aimed to study the impact of the new definition on the epidemiology of fatty liver disease.We randomly selected 922 adults from the Hong Kong census database for clinical assessment, proton-magnetic […]
• Constipation in Patients with Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit.1st November 2020
  Constipation can be an important symptom in some patients with gastroparesis. The aims were to: 1) Determine prevalence of constipation and delayed colonic transit in patients with symptoms of gastroparesis; 2) Correlate severity of constipation to severity of symptoms of gastroparesis; and 3) Relate severity of constipation to GI transit delays assessed by gastric emptying […]
• Population-Based Prevalence of Gastrointestinal Abnormalities at Colon Capsule Endoscopy.1st November 2020
  The population prevalence of gastrointestinal (GI) disease is unclear and difficult to assess in an asymptomatic population. The aim of this study was to determine prevalence of GI lesions in a largely asymptomatic population undergoing colon capsule endoscopy (CCE).Participants aged between 50-75years were retrieved from the Rotterdam Study, a longitudinal epidemiological study, between 2017-2019. Participants […]
• MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases.31st October 2020
  MicroRNAs (miRNAs) are small, non-coding RNAs that post-transcriptionally regulate gene expression by binding to specific mRNA targets and promoting their degradation and/or translational inhibition. miRNAs regulate both physiological and pathological liver functions. Altered expression of miRNAs is associated with liver metabolism dysregulation, liver injury, liver fibrosis and tumour development, making miRNAs attractive therapeutic strategies for […]
• Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn’s Disease: A Meta-Analysis of Population-based Cohorts.31st October 2020
  We conducted a systematic review with meta-analysis to estimate rates and trends of colectomy in patients with ulcerative colitis (UC), and of primary and re-resection in patients with Crohn’s disease (CD), focusing on contemporary risks.Through a systematic review till September 3, 2019, we identified population-based cohort studies that reported patient-level cumulative risk of surgery in […]
• Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis.31st October 2020
  Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The efficacy and safety of tofacitinib were demonstrated in a dose-ranging phase 2 induction trial, three phase 3 randomized, placebo-controlled trials (OCTAVE Induction 1 and 2; and OCTAVE Sustain), and an ongoing, open-label, long-term extension trial (OCTAVE Open) in […]
• Regeneration Defects in Yap and Taz Mutant Mouse Livers are Caused by Bile Duct Disruption and Cholestasis.31st October 2020
  The Hippo pathway and its downstream effectors YAP and TAZ (YAP/TAZ) are heralded as important regulators of organ growth and regeneration. However, different studies provided contradictory conclusions about their role during regeneration of different organs ranging from promoting proliferation to inhibiting it. Here, we resolve the function of YAP/TAZ during regeneration of the liver, where […]
• Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.27th October 2020
  The RHO family of GTPases, particularly RAC1, has been linked with hepatocarcinogenesis, suggesting that their inhibition might be a rational therapeutic approach. We aimed to identify and target deregulated RHO family members in human hepatocellular carcinoma (HCC).We studied expression deregulation, clinical prognosis and transcription programmes relevant to HCC using public datasets. The therapeutic potential of […]
• Acute-on-chronic liver failure: definition, prognosis and management.26th October 2020
  Acute-on-chronic liver failure (ACLF) is a recently described entity in chronic liver disease defined by acute hepatic decompensation, organ failure and a high risk of short-term mortality (usually less than 4 weeks). This condition is distinct from acute liver failure and stable progression of cirrhosis in numerous ways, including triggering precipitant factors, systemic inflammation, rapid […]
• Non-alcoholic fatty liver disease (NAFLD) in non-obese individuals.26th October 2020
  Individuals with non-alcoholic fatty liver disease (NAFLD) who lack classical risk factors also have the ability to develop nonalcoholic steatohepatitis (NASH) and progression to more advanced liver disease. The pathophysiology and risk factors for the development of NAFLD in non-obese persons are not fully understood but seem to be closely related to insulin resistance, atherogenic […]
• Variation in exposure to endoscopic haemostasis for acute upper gastrointestinal bleeding during UK gastroenterology training.26th October 2020
  Gastroenterologists are typically expected to be competent in endoscopic haemostasis for acute upper gastrointestinal bleeding (AUGIB), with the Certificate of Completion of Training (CCT) often heralding the onset of participation in on-call AUGIB rotas. We analysed the volume of haemostasis experience recorded by gastroenterology CCT holders on the Joint Advisory Group on Gastrointestinal Endoscopy Training […]
• New advances in the diagnosis and management of hepatocellular carcinoma.26th October 2020
  Hepatocellular carcinoma is one of the leading causes of cancer related death in the world. Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of hepatitis B virus allows early stage cancer detection and treatment with good long term outcomes. Liver ultrasonography and serum α fetoprotein are the most commonly […]
• Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy.24th October 2020
  Hepatic encephalopathy (HE) is a frequent and serious complication of both chronic liver disease and acute liver failure. HE manifests as a wide spectrum of neuropsychiatric abnormalities, from subclinical changes (mild cognitive impairment) to marked disorientation, confusion and coma. The clinical and economic burden of HE is considerable, and it contributes greatly to impaired quality […]
• TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection.24th October 2020
  Chronic hepatitis B virus (HBV) infection is characterised by HBV-specific CD8+ T cell dysfunction that has been linked to Tcell exhaustion, a distinct differentiation programme associated with persisting antigen recognition. Recently, Thymocyte Selection-Associated High Mobility Group Box (TOX) was identified as master regulator of CD8+ T cell exhaustion. Here, we addressed the role of TOX […]
• Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).20th October 2020
  Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP.GOG0209 was a phase III, randomized, noninferiority, open-label trial. Inclusion criteria were stage III, stage IV, and recurrent endometrial cancers; performance status 0-2; and […]
• Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide.20th October 2020
  Herpes zoster is a painful dermatomal cutaneous eruption due to the reactivation of the latent varicella-zoster virus. Patients with inflammatory bowel diseases have an increased risk of shingles compared to the general population and this risk can be increased with the use of immunosuppressive therapy. Live zoster vaccine and recombinant zoster vaccine have demonstrated efficacy […]
• Chronic Liver Disease and Metabolic Comorbidities in Healthy Young Males followed for 65 years: The Manitoba Follow-up Study.20th October 2020
  The prevalence of chronic liver disease (CLD) is largely derived from cross-sectional epidemiologic surveys. The goal of this long-term, prospective study was to document the lifetime risk of developing chronic liver disease and determine the impact of common metabolic conditions associated with metabolic syndrome (MetS) on the development and outcomes of CLD.3,983 air force men […]
• Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality.19th October 2020
  Distinct prognostic stages of advanced chronic liver disease (ACLD) are defined by severity of portal hypertension (PH) and the presence/absence of clinical complications. We characterized the degree of liver dysfunction, PH, and systemic inflammation (SI) across the distinct prognostic stages and assessed their relative impact on decompensation and mortality.A single-center, prospective cohort of ACLD patients […]
• Provider Attitudes and Practices for Alcohol Screening, Treatment and Education in Patients with Liver Disease: a Survey from the AASLD ALD SIG.18th October 2020
  While abstinence-promoting behavioral and pharmaco-therapies are part of the therapeutic foundation for alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), these therapies, along with alcohol screening and education, are often underutilized. Our aim was to examine provider attitudes and practices for alcohol screening, treatment and education in patients with liver disease.We conducted a survey […]
• Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.18th October 2020
  Hepatic encephalopathy (HE) is associated with increased morbidity, mortality, and healthcare resource use. In this phase 2b study, we evaluated the efficacy and safety of ornithine phenylacetate (OP), an ammonia scavenger, in hospitalized patients with cirrhosis, increased levels of ammonia at screening, and acute or overt HE.We conducted a double-blind study of 231 patients with […]
• Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV.18th October 2020
  Non-alcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to non-alcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons […]
• Guidelines on the management of ascites in cirrhosis.17th October 2020
  The British Society of Gastroenterology in collaboration with British Association for the Study of the Liver has prepared this document. The aim of this guideline is to review and summarise the evidence that guides clinical diagnosis and management of ascites in patients with cirrhosis. Substantial advances have been made in this area since the publication […]
• Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis.17th October 2020
  Wedge hepatic vein pressure (WHVP) accurately estimates portal pressure (PP) in alcohol or viral hepatitis-related cirrhosis. Whether this also holds true in cirrhosis due to non-alcoholic steatohepatitis (NASH) is unknown. We aimed to evaluate the agreement between WHVP and PP in patients with NASH cirrhosis in comparison with patients with alcohol or hepatitis C virus […]
• Nutritional approaches for gastroparesis.17th October 2020
  Patients with gastroparesis often have signs and symptoms including nausea, vomiting, epigastric discomfort, and early satiety, thus leading to inadequate food intake and a high risk of malnutrition. There is a considerable scarcity of data about nutritional strategies for gastroparesis, and current practices rely on extrapolated evidence. Some approaches include the modification of food composition, […]
• Targeting the gut-liver-immune axis to treat cirrhosis.16th October 2020
  Cirrhotic portal hypertension is characterised by development of the decompensating events of ascites, encephalopathy, portal hypertensive bleeding and hepatorenal syndrome, which arise in a setting of cirrhosis-associated immune dysfunction (CAID) and define morbidity and prognosis. CAID describes the dichotomous observations that systemic immune cells are primed and display an inflammatory phenotype, while failing to mount […]
• Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases.16th October 2020
  CT may miss up to 30% of cases of colorectal liver metastases (CRLM). We assessed the impact of contrast-enhanced ultrasound (CEUS) on the detection of CRLM and changes to the therapeutic strategy, and the accuracy of CEUS in differentiating unclear focal liver lesions (FLL) compared to staging-CT.We prospectively analyzed all patients with newly diagnosed and […]